When Novo Nordisk drastically reduced the price of their insulin NovoLog in 2023, it did not result in a less favorable formulary placement with Caremark. (01:24:24) And they were also asked if Ozempic and Wegovy were available for a hundred dollars per month or less, What impact do you expect that it would have on coverage and access? (01:24:34) Cigna Express says, If Novo Nordisk lowered the price for plan sponsors to a hundred dollars or less per patient per month, we would expect the vast majority of our clients to expand coverage and access to these products for diabetes and weight loss assuming clinical evidence continues to support efficacy and safety. (01:24:52) CVS said, Lower list prices would open up access for obesity treatment. In particular, United Health Group, Optum Rx, said, Given the significant price differential for these products across borders, a decision by Novo Nordisk to align US pricing more closely with those in other countries would meaningfully increase access for US patients. (01:25:11) So with that in mind, would you please commit to lowering the list price of these drugs
Neuroprotective actions of glucagon-like peptide-1 (glp-1) analogues in alzheimers and parkinsons diseases
Womens Dermatol 5 (5), 285307
Consider supportive peptides
Clinical evaluation of the pharmacological impact of ashwagandha root extract on sleep in healthy volunteers and insomnia patients: A double-blind, randomized, parallel-group, placebo-controlled study
